Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ARG1 | P05089 | 2/20 | 0.59 |
| ▸ | ARG2 | P78540 | 2/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172319 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL14743437 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL5283032 | 0.90 | ARG1 (0.51) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL27797467 | 0.90 | ARG1 (0.50) | SMN1; SMN2HIF1AARG1ARG2TAAR1 | |
| SCHEMBL14478223 | 0.89 | ARG1 (0.60) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL27469449 | 0.89 | ARG1 (0.60) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL8351006 | 0.88 | SMN1; SMN2 (0.69) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL5272379 | 0.87 | HIF1A (0.53) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL5272375 | 0.87 | HIF1A (0.53) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL12583580 | 0.87 | SMN1; SMN2 (0.53) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1630709-A | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2005-06-22 | — | — | CN | claimed |
| US-9687583-B2 | Adhesive biopolymers and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-06-27 | — | — | US | disclosed |
| US-20140371131-A1 | ADHESIVE BIOPOLYMERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-12-18 | — | — | US | disclosed |
| EP-2751132-A2 | ADHESIVE BIOPOLYMERS AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013030840-A2 | ADHESIVE BIOPOLYMERS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-03-07 | — | — | WO | disclosed |
| CN-101495502-A | N-terminally modified GLP-1 receptor modulators | BRISTOL MYERS SQUIBB CO (US) | 2009-07-29 | — | — | CN | disclosed |
| CN-1630709-A | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2005-06-22 | — | — | CN | disclosed |
| US-5268476-A | Substituted 10bH-oxazolo[3,2-c] [1,3] benzoxazine-2(3H), 5-diones | ABBOTT LABORATORIES (US) | 1993-12-07 | — | — | US | disclosed |
| US-5153358-A | Process for the preparation of alpha-alkylated alpha-amino acids and alpha-halogenated alpha-amino acids | ABBOTT LABORATORIES (US) | 1992-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371131-A1 | ADHESIVE BIOPOLYMERS AND USES THEREOF | ILK, ITGA2B, AOX1 | SMN1; SMN2 4476/4885HIF1A 1112/4885ARG1 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.